(September 12, 2022, 1:49 PM EDT) -- ALEXANDRIA, Va. — Various claims of a patented method of co-administering “familiar” doses of rivaroxaban and aspirin should be canceled, Teva Pharmaceuticals USA Inc. tells the Patent Trial and Appeal Board on Sept. 9 in a new petition for inter partes review (IPR)....